ABSTRACT
Introduction The rate of underlying ruptured aneurysm, complications, and outcomes in “benign” perimesencephalic subarachnoid hemorrhage (PMSAH) are not well known and underreported.
Methods Retrospective analysis of patients with PMSAH from a large tertiary care center (2007-2023). Clinical and imaging data were studied.
Results Eighty-one patients were included with mean age of 55.5 ± 10.3 years. Median (IQR) Hunt and Hess grade was 2 (1-2), and modified Fisher grade was 3 (1-3). An underlying ruptured aneurysm was diagnosed in 5 patients (6.2%). The most common complication was vasospasm in 25 patients (31%) with a significantly higher rate of symptomatic vasospasm among patients with underlying aneurysm (40% vs 2.6%; P=0.01). The median (IQR) time of vasospasm detection was 7 (8-9) days. The majority of vasospasm cases (84%) were asymptomatic, which was not associated with poor outcomes (OR= 0.95, [0.22–4.1], P=0.9) compared to the asymptomatic vasospasm (OR= 8.6, [1.06-69.88], P= 0.04). Hydrocephalus occurred in 10% of patients within one day, at higher rate in the aneurysmal group (40% vs 8%; P=0.07). A total of 88% of patients had a favorable functional outcome (mRS 0-2) at discharge, but at a significantly higher rate in non-aneurysmal patients (91% vs 40%; P=0.01). An underlying aneurysm and hydrocephalus were associated with poor functional status (OR= 14.7, [2.1–104], P=0.007, and OR= 22.6, [4.2–123.5], P <0.001), respectively.
Conclusion “Benign” PMSAH pattern was associated with a ruptured aneurysm in 6.2% of patients, which highlights the critical value of conventional cerebral angiogram in the workup. Expectedly, an underlying aneurysm was associated with higher rates of symptomatic vasospasm, hydrocephalus, and lower rates of good clinical outcome. Aneurysm and hydrocephalus were independently associated with poorer outcomes, however, these were detected very early during hospitalization. Vasospasm alone was not associated with poor outcomes. Our findings suggest that non-aneurysmal PMSAH patients can safely be managed with less strict monitoring and a shorter hospital stay.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cleveland Clinic institutional review board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos